Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment

Mesothelin (MSLN) is overexpressed by many cancers, including pancreatic ductal adenocarcinoma (PDAC) and has consequently become a target for anti-cancer therapeutics. Mature, membrane bound MSLN is cleaved by proteases, releasing a shed form that transits to the circulation. Many patients with mes...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Xianyu Zhang, Yunkai Yu, Cody J. Peer, Rebekah Landsman, Nebojsa Skorupan, Liang Cao, Christine Alewine
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2022-07-01
Edice:	Translational Oncology
Témata:	Pancreatic adenocarcinoma Microenvironment Mesothelin MUC16
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S1936523322000997
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!